The BENEFIT study showed that EGFR mutated NSCLC patients with concurrent alterations of tumor-suppressor genes or oncogenes were associated with shorter median PFS when treated with gefitinib [28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.